Athira Pharma(ATHA)

Search documents
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients
GlobeNewswire News Room· 2024-06-12 11:00
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint, the Global Statistical Test, designed to measure overall impact on disease Webinar event on Tuesday, June 18th at 11:30 a.m. ET BOTHELL, Wash., June 12, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage ...
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
Newsfilter· 2024-06-11 11:00
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy volunteers in its ongoing, first-in-human, dose escalation Phase 1 clinical study evaluating ATH-1105, an oral, small molecule positive modulator of the neurotrophic hepatocyte growth factor (HGF) system in development f ...
Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)
Prnewswire· 2024-06-10 12:00
SEATTLE, June 10, 2024 /PRNewswire/ -- Nacif, et al. v. Athira Pharma, Inc., et al., Case No: 2:21-cv-00861-TSZ (W.D. Wash).SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION AND PROPOSED SETTLEMENT; (II) FINAL APPROVAL HEARING;AND (III) MOTION FOR AN AWARD OF ATTORNEYS' FEESAND PAYMENT OF LITIGATION EXPENSESTO: All persons and entities who or which purchased or otherwise acquired Athira Pharma, Inc. ("Athira") publicly traded common stock during the period from September 17, 2020, through June 17, 2021, inclus ...
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
Newsfilter· 2024-05-17 21:00
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira against the individual defendants named in the previously disclosed stockh ...
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
globenewswire.com· 2024-05-17 21:00
Core Points - Athira Pharma, Inc. has received preliminary approval from the U.S. District Court for a proposed settlement related to stockholder derivative actions against individual defendants [1] - The settlement includes corporate governance reforms and payment of attorney's fees and expenses [1] - A final approval hearing is scheduled for July 18, 2024 [2] Company Overview - Athira Pharma is a late clinical-stage biopharmaceutical company based in the Seattle area, focusing on developing small molecules to restore neuronal health and slow neurodegeneration [3] - The company is advancing its pipeline, including fosgonimeton, which is being evaluated for treating mild-to-moderate Alzheimer's disease in a Phase 2/3 trial expected to report data in the second half of 2024 [3]
Athira Pharma(ATHA) - 2024 Q1 - Quarterly Report
2024-05-15 20:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------- ...
Athira Pharma(ATHA) - 2024 Q1 - Quarterly Results
2024-05-15 20:10
Exhibit 99.1 Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024 Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024 Strong balance ...
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Newsfilter· 2024-05-15 20:05
Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024 Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024 Strong balance sheet to support innovative pipeline through key clinical inflection points BOTHELL, Wash., May 15, 2024 ...
Athira Pharma to Participate in Upcoming May Conferences
Newsfilter· 2024-05-02 11:00
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May. Sidoti May 2024 Virtual Investor ConferenceFormat: Company PresentationDate and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET Location: Virtual The Citizens JM ...
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease
Newsfilter· 2024-04-11 11:00
BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer's disease. The original research article, "Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer's Disease," authored by Reda, S., et al., w ...